Navigation Links
Exciton Technologies receives FDA approval to market exSALT(TM)

EDMONTON, Aug. 5 /PRNewswire/ - Exciton Technologies Inc. today announced that the Company has received approval from the United States Food and Drug Administration (FDA) to market exSALT(TM) SD7 Wound Dressing, a product incorporating Exciton's patented platform coating technology utilizing silver oxysalts as the active ingredient.

"This achievement represents a significant team effort and a strong belief in our product," stated Rod Precht, Exciton's President and Chief Executive Officer. "To date, our technologies have demonstrated superior attributes over other leading silver technologies, allowing us to offer effective products at a significantly lower cost. With the approval from the FDA, we can now finalize our commercialization efforts to launch the exSALT(TM) dressing in North America later this year. In addition to preparing for the launch of the exSALT(TM) dressing, the Company is currently in the process of negotiating licensing and distribution agreements with leading wound care companies to broaden our marketing network globally."

The global wound-care market was $14 billion in 2008 and is expected to exceed $17 billion by 2012. Although silver-based products currently comprise a relatively small portion of this market, it is rapidly growing by 25% annually and is expected to grow to $750 million by 2015 due to the natural therapeutic benefits of silver. According to the Centers for Disease Control and Prevention, hospital-acquired infections in the United States alone cost up to $30 billion a year. Exciton's silver-based products have the potential to capitalize an even larger market by:

    -   Utilizing a more active form of silver;
    -   Reducing costs; and
    -   Being amendable to more applications such as consumer products,
        catheters and orthopedic devices.

    About exSALT(TM)

Silver has powerful antimicrobial properties. In the proper chemical form, it is proven as a highly effective wound-care agent with important benefits for promoting healing and preventing infection. Exciton's exSALT(TM) antimicrobial technology uses a patented chemical deposition technique to form a coating of active species of silver on a wide range of materials. The exSALT(TM) SD7 Wound Dressing targets the advanced wound care market in preventing infection during the treatment of burn and chronic wounds such as diabetic foot ulcers and bed sores. By adjusting the dose of silver and expanding the number of product configurations, Exciton can target a greater portion of the overall market.

    About Exciton Technologies Inc.

Exciton Technologies Inc. is an Alberta advanced materials research and development company focused on the creation of technologies for preventing and controlling infection. Currently our valuable portfolio of patentable platform technologies is based on the antimicrobial properties of silver. The Company's technologies offer next-generation, less expensive and environmentally friendly products, enabling the company to participate in many industries, including the wound care and disinfectant markets.

    Forward-looking Statements

This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.

SOURCE Exciton Technolgies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
3. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
4. OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.
5. Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software
6. Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
7. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
8. Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies
9. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
10. DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies
11. 4th BTLtec Conference on 24-25 Sep in Graz, Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies, Syngas Application, BTL Value Chain and a Site Visit to the Biomass CHP Gussing Plant.
Post Your Comments:
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... ... , ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, ... serve as Chief Operating Officer. , Having joined InSphero in November 2013 ... was promoted to Head of InSphero Diagnostics in 2014. There she has built ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. ... that Mr. Pierre Laurin , President and Chief Executive ... the upcoming Piper Jaffray 27 th Annual Healthcare Conference ... December 1-2, 2015. st , at 8.50am ... meetings throughout the day. The presentation will be available live ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):